17 May 2024
Latham & Watkins Advises Allogene Therapeutics in Pricing of US$110 Million Offering of Common Stock
Advising firms
Deal team
6 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Shayne Kennedy Lead | Latham & Watkins LLP | Partner | capital markets | Orange County |
| Phillip Stoup | Latham & Watkins LLP | Partner | capital markets | Bay Area |
| Tess Bloom | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Taimi Jacobson | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Judith Hasko | Latham & Watkins LLP | Partner | IP | Bay Area |
| Patrick Chew | Latham & Watkins LLP | Associate | IP | Not stated |
3 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 110m (US$110 million)
- What the figure measures
- Issue size
- Client
- Allogene Therapeutics, Inc.Issuer
- Counterparties
- sole book-running manager (Underwriters)